RT Journal Article
SR Electronic
T1 Vaccine effectiveness against mild and severe disease in pregnant mothers and their infants in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.07.23290978
DO 10.1101/2023.06.07.23290978
A1 Kirsebom, Freja C M
A1 Andrews, Nick
A1 Mensah, Anna A
A1 Stowe, Julia
A1 Ladhani, Shamez N
A1 Ramsay, Mary
A1 Lopez Bernal, Jamie
A1 Campbell, Helen
YR 2023
UL http://medrxiv.org/content/early/2023/06/10/2023.06.07.23290978.abstract
AB Background Pregnant women are at increased risk of adverse outcomes following SARS-CoV-2 infection, including venous thromboembolism, admission to critical care and death. Their infants may also suffer from pre-term birth, stillbirth and severe disease. Vaccination may protect both mothers and their infants against severe COVID-19 disease.Methods We used a test-negative, case-control study design to estimate vaccine effectiveness against symptomatic disease and hospitalisation with the Delta and Omicron variants in pregnant women who gave birth in 2021 in England. We also estimated the protection conferred by prior infection and maternal vaccination against symptomatic disease and hospitalisation with the Delta and Omicron variants in their infants.Findings Vaccine effectiveness against symptomatic disease (Delta and Omicron) and against hospitalisation (Delta only) was high and similar to that observed in the general population. Maternal vaccination during and post-pregnancy as well as previous infection also provided sustained protection from symptomatic disease and hospitalisation following Delta and Omicron infection in infants up to 8 months of age, with the highest protection being observed when maternal vaccination occurred during later pregnancy. Unlike non-pregnant women, a booster dose provided sustained protection with no evidence of waning up to 15 weeks after vaccination.Interpretation Maternal vaccination prevents mild and severe disease in pregnant women and their infants up to 6-8 months after birth. Our findings support the promotion of both primary and booster vaccination for pregnant women, irrespective of prior infection status, to protect themselves and their infants.Funding None.Evidence before this study Pregnant women were included in the UK’s priority risk groups for COVID-19 vaccination from 2 December 2021 when they were encouraged to complete vaccination with an mRNA booster vaccine of either Pfizer BioNTech or Moderna. We searched PubMed using the terms ‘pregnancy’, ‘COVID-19’, ‘vaccine’ and ‘vaccine effectiveness’, with no date restrictions on 1 March 2023, and used the snowball process to identify additional relevant publications. We also scoped preprint databases for relevant COVID-19 vaccine effectiveness studies undertaken after the emergence of the more immune-evasive Omicron variant from December 2021. Studies have shown moderate COVID-19 vaccine effectiveness after a second dose in pregnant women against symptomatic Omicron disease with evidence that booster doses of mRNA vaccines confer higher protection against serious Omicron disease, comparable with population-based immunity. In addition to evidence of transplacental transfer of maternal antibody, real-life evidence from test-negative case-control studies have demonstrated protection in infants following maternal vaccination which is highest after vaccination in the third trimester and wanes with increasing infant age.Added value of this study Ours is the largest study of the effectiveness of maternal COVID-19 vaccines against both maternal and infant disease, in addition to the protection conferred by past infection in the mother to the infant. In pregnant women, vaccine effectiveness against symptomatic Delta and Omicron infection, and against hospitalisation with Delta, remained high after vaccination with limited waning observed at the longest time points investigated post vaccination. Both prior infection and maternal vaccination protected infants after birth against symptomatic disease and hospitalisation with Delta and Omicron. Vaccine effectiveness was highest when maternal vaccination occurred in the later stages of pregnancy.Implications of all the available evidence These findings support the benefits of maternal vaccination in preventing disease in the mother and in her infant in the first months of life, regardless of prior infection status in the mother. Policy decisions need to balance the suggestion of higher protection after vaccination later in pregnancy with the need to ensure adequate opportunities for vaccination before women reach the pregnancy stage when they are at greatest risk from COVID-19 disease and to optimise the infant benefit even in pre-term births.Competing Interest StatementThe Immunisation Department provides vaccine manufacturers (including Pfizer) with post-marketing surveillance reports about pneumococcal and meningococcal disease which the companies are required to submit to the UK Licensing authority in compliance with their Risk Management Strategy. A cost recovery charge is made for these reports.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Surveillance of coronavirus disease 2019 (Covid-19) testing and vaccination is undertaken under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002 to collect confidential patient information (www.legislation.gov.uk/uksi/2002/1438/regulation/3/made. opens in new tab) under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii), and 3. The study protocol was subject to an internal review by the UKHSA (formerly Public Health England) Research Ethics and Governance Group and was found to be fully compliant with all regulatory requirements. Given that no regulatory issues were identified and that ethics review is not a requirement for this type of work, it was decided that a full ethics review would not be necessary.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript in aggregate.